Suchergebnisse - Portal für Medizinische Datenmodelle (MDM-Portal)

Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma NCT00992758 - Week 3 - 13 and 25 - Laboratory Results; Physical Examination; Post-Treatment Response

- 30.03.21 - 1 Formular, 19 Itemgruppen, 62 Datenelemente, 1 Sprache

Itemgruppen: Administrative, Laboratory Results (Week 3-13, 25) - Hematology, Laboratory Results (Week 3-13, 25) - Hematology, Laboratory Results (Week 25) - Hematology , Laboratory Results (Week 3, 13, 25) - Chemistry, Laboratory Results (Week 3 and 13) - Chemistry, Laboratory Results (Week 7) - Chemistry, Laboratory Results (Week 7) - Chemistry , Laboratory Results (Week 25) - Chemistry , Physical Examination (Week 7, 13, 25), Physical Examination (Week 7, 13, 25), Post-Treatment Response (Week 7, 13, 25) - CT or other Radiological Imaging Results, Post-Treatment Response (Week 7, 13, 25) - Bone Marrow Biopsy, Post-Treatment Response (Week 7 and 13) - Received medication/transfusion, Post-Treatment Response (Week 7, 13, 25) - Measurable Lymphoma Disease, Post-Treatment Response (Week 7, 13, 25) - Non-Measurable Lymphoma Disease, Post-Treatment Response (Week 7, 13, 25) - Non-Measurable Lymphoma Disease, Post-Treatment Response (Week 7, 13, 25) - Response, Signature of Investigator

Study ID: 104512 Clinical Study ID: 104512 Study Title: Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma With More Than 25% Bone Marrow Involvement Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00992758 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Iodine-131 Anti-B1 Antibody Trade Name: Tositumomab Study Indication: Lymphoma, Non-Hodgkin

Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma NCT00992758 - Baseline - Physical Examination; Laboratory Results; Disease Staging

- 25.03.21 - 1 Formular, 14 Itemgruppen, 55 Datenelemente, 1 Sprache

Itemgruppen: Administrative, Physical Examination (Baseline), Physical Examination (Baseline) , Laboratory Results (Baseline) - Hematology, Laboratory Results (Baseline) - Hematology, Laboratory Results (Baseline) - Chemistry, Laboratory Results (Baseline) - Chemistry, Pregnancy Test (Baseline), Disease Staging - CT or other Radiological Imaging Results (Baseline), Disease Staging - Bone Marrow Biopsy (Baseline), Disease Staging - Measurable Lymphoma Disease (Baseline), Disease Staging - Non-Measurable Lymphoma Disease (Baseline) , Disease Staging - Non-Measurable Lymphoma Disease (Baseline) , Signature of Investigator

Study ID: 104512 Clinical Study ID: 104512 Study Title: Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma With More Than 25% Bone Marrow Involvement Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00992758 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Iodine-131 Anti-B1 Antibody Trade Name: Tositumomab Study Indication: Lymphoma, Non-Hodgkin

Oral GW786034 treatment for ovarian cancer NCT00281632 - Screening

- 15.03.21 - 1 Formular, 24 Itemgruppen, 129 Datenelemente, 2 Sprachen

Itemgruppen: Header, Eligibility Question, Demography, Physical examination, Disease Characteristics, Metastatic Disease Site, local laboratory, Residual toxicities related to previous therapy for cancer, Residual toxicities, Cancer related current medical conditions, Medical Conditions, non-cancer related medical conditions, Medical Conditions, Prior anti-cancer therapy, Prior anti-cancer therapy - medication, Prior anti-cancer therapy - radiotherapy, Vital signs, ECOG Performance Status Scale, 12 LEAD ECG, 12-lead ECG Abnormalities, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, Urinalysis, Electronically transferred laboratory data

Study ID: 104450 Clinical Study ID: VEG104450 Study Title: This study is a non-randomized, open-label, multi-center Phase II study of GW786034 to evaluate the administration of oral GW786034 in subjects with ovarian cancer. Clinicaltrials.gov Identifier: NCT00281632 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib Trade Name: Votrient Study Indication: Neoplasms, Ovarian CRF Pages: 722-853

Ropinirole prolonged release (PR) as adjunctive treatment to L-Dopa in patients with advanced Parkinson's disease (NCT01494532) - Visit 1; Visit 2; Visit 3; Visit 4; Visit 5; Visit 6; Visit 7; Visit 8; Visit Maintenance 1 +2; Early Withdrawal; Follow up; Optional Visit; Unscheduled - PR/Conmeds; SOOS; Vitals

- 15.03.21 - 1 Formular, 8 Itemgruppen, 54 Datenelemente, 1 Sprache

Itemgruppen: Administrative, Prior/ Current Concomitant Medications, Prior/ current non-drug therapies, Non-drug therapies, Sudden Onset of Sleep Questionnaire, Vital Signs - Semi supine , Vital Signs - Standing , Physical Exam

Study ID: 111569 Clinical Study ID: 111569 Study Title: A fixed dose, dose-response study for ropinirole prolonged release (PR) as adjunctive treatment to L-Dopa in patients with advanced Parkinson's disease Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01494532 Sponsor: GlaxoSmithKline Phase: Phase 4 Study Recruitment Status: Completed Generic Name: Ropinirole, placebo Study Indication: Parkinson's Disease